Vor Bio Doses First Patient in Global Phase 3 UPSTREAM SjD Registrational Trial of Telitacicept in Primary Sjögren’s Disease
Vor Biopharma Inc. (VOR)
Company Research
Source: GlobeNewswire
BOSTON, March 30, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the dosing of the first patient in UPSTREAM SjD, a global, randomized, double-blind, placebo-controlled Phase 3 trial evaluating telitacicept in adult patients with active primary Sjögren’s disease (SjD), formerly known as Sjögren's syndrome. “Dosing the first patient in the global Phase 3 UPSTREAM SjD trial represents a significant milestone for telitacicept and for patients living with Sjögren’s disease. As the only BAFF/APRIL inhibitor currently in Phase 3 development for this condition, we believe telitacicept has the potential to address a serious autoimmune disease that currently lacks approved disease-modifying therapies,” said Jean-Paul Kress, M.D., Chief Executive Officer and Chairman of Vor Bio. “In late 2025, RemeGen presented results from a Phase 3 trial conducted in China with telitacicept in the sam
Show less
Read more
Impact Snapshot
Event Time:
VOR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VOR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VOR alerts
High impacting Vor Biopharma Inc. news events
Weekly update
A roundup of the hottest topics
VOR
News
- Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Vor Biopharma (VOR) had its price target raised by Wedbush from $9.00 to $15.00. They now have a "neutral" rating on the stock.MarketBeat
- Vor Biopharma (VOR) was upgraded by Jefferies Financial Group Inc. to "strong-buy".MarketBeat
- Vor Biopharma (VOR) is now covered by Jefferies Financial Group Inc.. They set a "buy" rating and a $50.00 price target on the stock.MarketBeat
- Vor Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateGlobeNewswire
VOR
Earnings
- 3/30/26 - Miss
VOR
Sec Filings
- 4/1/26 - Form SCHEDULE
- 4/1/26 - Form 3
- 4/1/26 - Form SCHEDULE
- VOR's page on the SEC website